Literature DB >> 11906176

Catecholestrogen sulfation: possible role in carcinogenesis.

Araba A Adjei1, Richard M Weinshilboum.   

Abstract

A growing body of evidence supports the hypothesis that estrogens can be carcinogens as a result of their conversion to genotoxins after biotransformation to form the catecholestrogens (CEs) 2-hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-OHE2), 4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2). CEs can then undergo further metabolism to form quinones that interact with DNA to form either stable or depurinating adducts. These events could potentially be interrupted by the sulfate conjugation of both the parent estrogens and/or the CEs. We set out to determine whether CEs can serve as substrates for sulfate conjugation, and-if so-which of the growing family of human sulfotransferase (SULT) isoforms are capable of catalyzing those reactions. We determined apparent K(m) values for 10 recombinant human SULT isoforms, as well as the three most common allozymes for SULT1A1 and SULT1A2, with 2-OHE1, 2-OHE2, 4-OHE1, and 4-OHE2, and with the endogenous estrogens, estrone (E1) and 17beta-estradiol (E2), as substrates. With the exception of SULT1B1, SULT1C1, and SULT4A1, all of the human SULTs studied catalyzed the sulfate conjugation of CEs. SULT1E1 had the lowest apparent K(m) values, 0.31, 0.18, 0.27, and 0.22 microM for 4-OHE1, 4-OHE2, 2-OHE1, and 2-OHE2, respectively. These results demonstrate that SULTs can catalyze the sulfate conjugation of CEs, and they raise the possibility that individual variation in this pathway for estrogen and CE metabolism as a result of common genetic polymorphisms could represent a risk factor for estrogen-dependent carcinogenesis. (c)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906176     DOI: 10.1006/bbrc.2002.6658

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Frank Z Stanczyk; Kim C Westerlind; Katherine M Newton; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  J Steroid Biochem Mol Biol       Date:  2010-12-28       Impact factor: 4.292

Review 2.  Sulfotransferase gene copy number variation: pharmacogenetics and function.

Authors:  S J Hebbring; A M Moyer; R M Weinshilboum
Journal:  Cytogenet Genome Res       Date:  2009-03-11       Impact factor: 1.636

3.  The inhibitory effect of bamboo extract on the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer.

Authors:  Yanling Lin; Abby C Collier; Wanyu Liu; Marla J Berry; Jun Panee
Journal:  Phytother Res       Date:  2008-11       Impact factor: 5.878

4.  Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis.

Authors:  Kelly E Mercer; Eugene O Apostolov; Goncalo Gamboa da Costa; Xinfeng Yu; Patrick Lang; Dean W Roberts; Warren Davis; Alexei G Basnakian; Fred F Kadlubar; Susan A Kadlubar
Journal:  Int J Mol Epidemiol Genet       Date:  2010-01-30

5.  Relationship of SULT1A1 copy number variation with estrogen metabolism and human health.

Authors:  Jixia Liu; Ran Zhao; Zhan Ye; Alexander J Frey; Emily R Schriver; Nathaniel W Snyder; Scott J Hebbring
Journal:  J Steroid Biochem Mol Biol       Date:  2017-09-01       Impact factor: 4.292

6.  SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women.

Authors:  Shimrit Cohen; Yael Laitman; Bella Kaufman; Roni Milgrom; Uri Nir; Eitan Friedman
Journal:  Fam Cancer       Date:  2008-09-27       Impact factor: 2.375

7.  Allosteric modulation of SULT2A1 by celecoxib and nimesulide: computational analyses.

Authors:  Emine Bihter Yalcin; Scott M Struzik; Roberta S King
Journal:  Drug Metab Lett       Date:  2008-08

8.  Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Authors:  Federico Innocenti; Jacqueline Ramírez; Jennifer Obel; Julia Xiong; Snezana Mirkov; Yi-Lin Chiu; David A Katz; Robert A Carr; Wei Zhang; Soma Das; Araba Adjei; Ann M Moyer; Pei Xian Chen; Andrew Krivoshik; Diane Medina; Gary B Gordon; Mark J Ratain; Leonardo Sahelijo; Richard M Weinshilboum; Gini F Fleming; Anahita Bhathena
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

9.  Concerted actions of the catechol O-methyltransferase and the cytosolic sulfotransferase SULT1A3 in the metabolism of catecholic drugs.

Authors:  Katsuhisa Kurogi; Adnan Alazizi; Ming-Yih Liu; Yoichi Sakakibara; Masahito Suiko; Takuya Sugahara; Ming-Cheh Liu
Journal:  Biochem Pharmacol       Date:  2012-08-16       Impact factor: 5.858

10.  Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics.

Authors:  Araba A Adjei; Bianca A Thomae; Janel L Prondzinski; Bruce W Eckloff; Eric D Wieben; Richard M Weinshilboum
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.